title: Real world points to SGLT-2 blockers advantage.
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D000068896:Canagliflozin / Q000627:therapeutic use; D018376:Cardiovascular Abnormalities / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D005947:Glucose / Q000378:metabolism; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D007687:Kidney Tubules, Proximal / Q000187:drug effects; D051297:Sodium-Glucose Transporter 2 / Q000627:therapeutic use; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000068896:Canagliflozin; C529054:dapagliflozin; D005947:Glucose